Cell-level dosimetry and biologic response modeling of heterogeneously distributed radionuclides: A step forward

Journal of Nuclear Medicine

Volumn 52, Issue 6, 2011, Pages 845-847

  Zanzonico, Pat ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH 213; EDRECOLOMAB; INDIUM 111; IODINE 125; IODINE 131; RADIOISOTOPE; SODIUM IODIDE SYMPORTER; YTTRIUM 90;

CELL ACTIVITY; CELL CULTURE; CELL LEVEL; CELL NUCLEUS; CELL POPULATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; DOSIMETRY; GENETIC TRANSDUCTION; HUMAN; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIATION RESPONSE; REVIEW; TISSUE CULTURE;

CELLS; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; RADIOISOTOPES; RADIOMETRY; RADIOTHERAPY; TISSUE CULTURE TECHNIQUES;

EID: 79958092582     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.087841     Document Type: Review

References (25)

1. Zanzonico P, Brill A, Becker D. Radiation dosimetry. In: Wagner H, Szabo Z, Buchanan J, eds. Principles of Nuclear Medicine. 2nd ed. Philadelphia: WB Saunders Comp; 1995:106-134.
2. Zanzonico PB. Internal radionuclide radiation dosimetry: a review of basic concepts and recent developments. J Nucl Med. 2000;41:297-308. (Pubitemid 30091351)
3. Behr TM, Behe M, Sgouros G. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Cancer Biother Radiopharm. 2002;17:445-464.
4. O'Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med. 1999;40:1337-1341. (Pubitemid 29385643)
5. Behr TM, Sgouros G, Stabin MG, et al. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters. Clin Cancer Res. 1999;5:3031s-3043s.
6. 131I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer. 1998;76:738-748.
7. Behr TM, Sharkey RM, Juweid ME, et al. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies. J Nucl Med. 1997;38:409-418. (Pubitemid 27376894)
8. Behr TM, Sharkey RM, Sgouros G, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer. 1997;80:2591-2610. (Pubitemid 28009516)
9. Neti PV, Howell RW. When may a nonuniform distribution of 131I be considered uniform? An experimental basis for multicellular dosimetry. J Nucl Med. 2003;44:2019-2026. (Pubitemid 40022148)
10. Zanzonico P, Sgouros G. Predicting myelotoxicity in radioimmunotherapy: what does dosimetry contribute? J Nucl Med. 1997;38:1753-1754.
11. Rajon R, Bolch WE, Howell RW. Lognormal distribution of cellular uptake of radioactivity: Monte Carlo simulation of irradiation and cell killing in 3-dimensional populations in carbon scaffolds. J Nucl Med. 2011;52:926-933.
12. Carlin S, Cunningham SH, Boyd M, et al. Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two-and three-dimensional models. Cancer Gene Ther. 2000;7:1529-1536. (Pubitemid 32098764)
13. 131I]IUdR to human glioma cells in monolayer or spheroid culture: effect of proliferative heterogeneity and radiation cross-fire. Br J Cancer. 1998;77:385-390.
14. Pinto M, Azzam EI, Howell RW. Bystander responses in three-dimensional cultures containing radiolabelled and unlabelled human cells. Radiat Prot Dosimetry. 2006;122:252-255. (Pubitemid 47090459)
15. 213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res. 2001;61:2008-2014.
16. Ballangrud AM, Yang WH, Dnistrian A, et al. Growth and characterization of LNCaP prostate cancer cell spheroids. Clin Cancer Res. 1999;5:3171s-3176s.
17. Ballangrud AM, Yang WH, Palm S, et al. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res. 2004;10:4489-4497. (Pubitemid 38878893)
18. Emfietzoglou D, Kostarelos K, Papakostas A, et al. Liposome-mediated radiotherapeutics within avascular tumor spheroids: comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody. J Nucl Med. 2005;46:89-97. (Pubitemid 43086002)
19. Bardies M, Thedrez P, Gestin JF, et al. Use of multi-cell spheroids of ovarian carcinoma as an intraperitoneal radio-immunotherapy model: uptake, retention kinetics and dosimetric evaluation. Int J Cancer. 1992;50:984-991.
20. Buchsbaum DJ, Langmuir VK, Wessels BW. Experimental radioimmunotherapy. Med Phys. 1993;20:551-567.
21. Goddu SM, Rao DV, Howell RW. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J Nucl Med. 1994;35:521-530. (Pubitemid 24079989)
22. Howell RW, Neti PV. Modeling multicellular response to nonuniform distributions of radioactivity: differences in cellular response to self-dose and cross-dose. Radiat Res. 2005;163:216-221. (Pubitemid 40170772)
23. 131I on labeled and unlabeled cells. J Nucl Med. 2004;45:1050-1058.
24. Neti PV, Howell RW. Log normal distribution of cellular uptake of radioactivity: implications for biologic responses to radiopharmaceuticals. J Nucl Med. 2006;47:1049-1058. (Pubitemid 46939959)
25. Akudugu JM, Neti PV, Howell RW. Changes in lognormal shape parameter guide design of patient-specific radiochemotherapy cocktails. J Nucl Med. 2011;52:642-649.